Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology

References

• 1 Cancer Facts & Figures 2012. www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012.
  Google Scholar
• 2 Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy – revisited. Nat. Rev. Drug Discov. 10(8), 591–600 (2011).
  Medline CASGoogle Scholar
• 3 Dillman RO. Cancer immunotherapy. Cancer Biother. Radiopharm. 26(1), 1–64 (2011).
  Medline CASGoogle Scholar
• 4 Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543–547 (2011).
  Medline CASGoogle Scholar
• 5 Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196–200 (2002).
  Medline CASGoogle Scholar
• 6 Smith KA. T-cell growth factor. Immunol. Rev. 51, 337–357 (1980).
  Medline CASGoogle Scholar
• 7 Abbas AK, Janeway CJ. Immunology: improving on nature in the twenty-first century. Cell 100(1), 129–138 (2000).
  Medline CASGoogle Scholar
• 8 Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy. Eur. J. Cell Biol. 91(1), 53–58 (2012).
  Medline CASGoogle Scholar
• 9 Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer – what clinicians need to know. Nat. Rev. Clin. Oncol. 8(10), 577–585 (2011).
  Medline CASGoogle Scholar
• 10 Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991–998 (2002).
  Medline CASGoogle Scholar
• 11 Wheelock EF, Weinhold KJ, Levich J. The tumor dormant state. Adv. Cancer Res. 34, 107–140 (1981).
  Medline CASGoogle Scholar
• 12 Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).
  Medline CASGoogle Scholar
• 13 Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21(9), 455–464 (2000).
  Medline CASGoogle Scholar
• 14 Li W, Zhao MX, Ke C et al. Nano polymeric carrier fabrication technologies for advanced antitumor therapy. Biomed. Res. Int. 2013, 305089 (2013).
  MedlineGoogle Scholar
• 15 Carstens MG. Opportunities and challenges in vaccine delivery. Eur. J. Pharm. Sci. 36(4–5), 605–608 (2009).
  Medline CASGoogle Scholar
• 16 Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol. 2011, 732413 (2011).
  MedlineGoogle Scholar
• 17 Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res. 15(24), 7471–7478 (2009).
  Medline CASGoogle Scholar
• 18 Settleman J. Oncogene addiction. Curr. Biol. 22(2), R43–R44 (2012).
  Medline CASGoogle Scholar
• 19 Banck MS, Grothey A. Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin. Cancer Res. 15(24), 7492–7501 (2009).
  Medline CASGoogle Scholar
• 20 Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J. 16(4), 311–317 (2010).
  Medline CASGoogle Scholar
• 21 Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010).
  Medline CASGoogle Scholar
• 22 Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol. Ther. 138(3), 452–469 (2013).
  Medline CASGoogle Scholar
• 23 Mocellin S, Rossi CR, Nitti D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp. Cell Res. 299(2), 267–278 (2004).
  Medline CASGoogle Scholar
• 24 Li W, Li H, Li J et al. Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors. Int. J. Nanomedicine 7, 4661–4677 (2012).
  Medline CASGoogle Scholar
• 25 Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev. Vaccines 6(5), 797–808 (2007).
  Medline CASGoogle Scholar
• 26 Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol. Immunother. 57(4), 517–530 (2008).
  Medline CASGoogle Scholar
• 27 Mesa C, Fernandez LE. Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell Biol. 82(6), 644–650 (2004).
  Medline CASGoogle Scholar
• 28 Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev. Vaccines 9(10), 1149–1176 (2010).
  Medline CASGoogle Scholar
• 29 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909–915 (2004).
  Medline CASGoogle Scholar
• 30 Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3(8), 630–641 (2003).
  Medline CASGoogle Scholar
• 31 Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9(9), 1095–1107 (2010).
  Medline CASGoogle Scholar
• 32 Mellado MC, Mena JA, Lopes A et al. Impact of physicochemical parameters on in vitro assembly and disassembly kinetics of recombinant triple-layered rotavirus-like particles. Biotechnol. Bioeng. 104(4), 674–686 (2009).
  Medline CASGoogle Scholar
• 33 Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263–274 (2005).
  Medline CASGoogle Scholar
• 34 Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295–307 (2006).
  Medline CASGoogle Scholar
• 35 Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8(3), 277–284 (2007).
  Medline CASGoogle Scholar
• 36 Ding B, Wu X, Fan W et al. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int. J. Nanomedicine 6, 1991–2005 (2011).
  Medline CASGoogle Scholar
• 37 Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol. 732413 (2011).
  MedlineGoogle Scholar
• 38 Li W, Feng SS, Guo Y. Polymeric nanoparticulates for cancer immunotherapy. Nanomedicine (Lond.) 8(5), 679–682 (2013).
  CASGoogle Scholar
• 39 Li W, Zhang L, Zhang G et al. The finely regulating well-defined functional polymeric nanocarriers for anti-tumor immunotherapy. Mini Rev. Med. Chem. 13(5), 643–652 (2013).
  Medline CASGoogle Scholar
• 40 Li W, Zhao H, Qian W et al. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 33(21), 5349–5362 (2012).
  Medline CASGoogle Scholar
• 41 Zaric M, Lyubomska O, Touzelet O et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D, L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano 7(3), 2042–2055 (2013).
  Medline CASGoogle Scholar
• 42 Blank F, Gerber P, Rothen-Rutishauser B et al. Biomedical nanoparticles modulate specific CD4⁺ T cell stimulation by inhibition of antigen processing in dendritic cells. Nanotoxicology 5(4), 606–621 (2011).
  Medline CASGoogle Scholar
• 43 Kasturi SP, Skountzou I, Albrecht RA et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543–547 (2011).
  Medline CASGoogle Scholar
• 44 Uto T, Wang X, Sato K et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J. Immunol. 178(5), 2979–2986 (2007).
  Medline CASGoogle Scholar
• 45 Wang X, Uto T, Akagi T, Akashi M, Baba M. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J. Med. Virol. 80(1), 11–19 (2008).
  Medline CASGoogle Scholar
• 46 Yoshikawa T, Okada N, Oda A et al. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26(10), 1303–1313 (2008).
  Medline CASGoogle Scholar
• 47 Akagi T, Wang X, Uto T, Baba M, Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 28(23), 3427–3436 (2007).
  Medline CASGoogle Scholar
• 48 Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J. Enhanced antigen-specific primary CD4⁺ and CD8⁺ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J. Biomed. Mater. Res. A 81(3), 652–662 (2007).
  MedlineGoogle Scholar
• 49 Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 25(19), 3731–3741 (2007).
  Medline CASGoogle Scholar
• 50 Hobo W, Novobrantseva TI, Fredrix H et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol. Immunother. 62(2), 285–297 (2013).
  Medline CASGoogle Scholar
• 51 Park IY, Kim IY, Yoo MK, Choi YJ, Cho MH, Cho CS. Mannosylated polyethylenimine coupled mesoporous silica nanoparticles for receptor-mediated gene delivery. Int. J. Pharm. 359(1–2), 280–287 (2008).
  Medline CASGoogle Scholar
• 52 Mishra D, Mishra PK, Dabadghao S, Dubey V, Nahar M, Jain NK. Comparative evaluation of hepatitis B surface antigen-loaded elastic liposomes and ethosomes for human dendritic cell uptake and immune response. Nanomedicine 6(1), 110–118 (2010).
  Medline CASGoogle Scholar
• 53 Minigo G, Scholzen A, Tang CK et al. Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine 25(7), 1316–1327 (2007).
  Medline CASGoogle Scholar
• 54 Cubillos-Ruiz JR, Engle X, Scarlett UK et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 119(8), 2231–2244 (2009).
  Medline CASGoogle Scholar
• 55 Flanary S, Hoffman AS, Stayton PS. Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconjug. Chem. 20(2), 241–248 (2009).
  Medline CASGoogle Scholar
• 56 Tang R, Palumbo RN, Nagarajan L, Krogstad E, Wang C. Well-defined block copolymers for gene delivery to dendritic cells: probing the effect of polycation chain-length. J. Control. Release 142(2), 229–237 (2010).
  Medline CASGoogle Scholar
• 57 Eby JK, Dane KY, O'Neil CP, Hirosue S, Swartz MA, Hubbell JA. Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization. Acta Biomater. 8(9), 3210–3217 (2012).
  Medline CASGoogle Scholar
• 58 Boudier A, Aubert-Pouessel A, Mebarek N et al. Development of tripartite polyion micelles for efficient peptide delivery into dendritic cells without altering their plasticity. J. Control. Release 154(2), 156–163 (2011).
  Medline CASGoogle Scholar
• 59 Cheng C, Convertine AJ, Stayton PS, Bryers JD. Multifunctional triblock copolymers for intracellular messenger RNA delivery. Biomaterials 33(28), 6868–6876 (2012).
  Medline CASGoogle Scholar
• 60 Demento SL, Eisenbarth SC, Foellmer HG et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27(23), 3013–3021 (2009).
  Medline CASGoogle Scholar
• 61 Hamdy S, Molavi O, Ma Z et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8⁺ T cell-mediated anti-tumor immunity. Vaccine 26(39), 5046–5057 (2008).
  Medline CASGoogle Scholar
• 62 Irache JM, Salman HH, Gamazo C, Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5(6), 703–724 (2008).
  Medline CASGoogle Scholar
• 63 Moon JJ, Suh H, Bershteyn A et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10(3), 243–251 (2011).
  Medline CASGoogle Scholar
• 64 Sneh-Edri H, Likhtenshtein D, Stepensky D. Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro. Mol. Pharm. 8(4), 1266–1275 (2011).
  Medline CASGoogle Scholar
• 65 Kwon YJ, Standley SM, Goh SL, Frechet JM. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J. Control. Release 105(3), 199–212 (2005).
  Medline CASGoogle Scholar
• 66 Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta 1770(4), 681–686 (2007).
  Medline CASGoogle Scholar
• 67 Nochi T, Yuki Y, Takahashi H et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9(7), 572–578 (2010).
  Medline CASGoogle Scholar
• 68 Pitaksuteepong T, Davies NM, Baird M, Rades T. Uptake of antigen encapsulated in polyethylcyanoacrylate nanoparticles by D1-dendritic cells. Pharmazie 59(2), 134–142 (2004).
  Medline CASGoogle Scholar
• 69 Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J. Immunother. 30(4), 378–395 (2007).
  Medline CASGoogle Scholar
• 70 Slutter B, Plapied L, Fievez V et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J. Control. Release 138(2), 113–121 (2009).
  Medline CASGoogle Scholar
• 71 Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28(35), 5344–5357 (2007).
  Medline CASGoogle Scholar
• 72 Mohanan D, Slutter B, Henriksen-Lacey M et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release 147(3), 342–349 (2010).
  Medline CASGoogle Scholar
• 73 Combadiere B, Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis. 31(2–3), 293–315 (2008).
  MedlineGoogle Scholar
• 74 Fuchs S, Klier J, May A, Winter G, Coester C, Gehlen H. Towards an inhalative in vivo application of immunomodulating gelatin nanoparticles in horse-related preformulation studies. J. Microencapsul. 29(7), 615–625 (2012).
  Medline CASGoogle Scholar
• 75 Sherwood JK, Dause RB, Saltzman WM. Controlled antibody delivery systems. Biotechnology (NY) 10(11), 1446–1449 (1992).
  Medline CASGoogle Scholar
• 76 Marroquin BO, Cordero MI, Setola V et al. Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool. PLoS ONE 6(4), e18268 (2011).
  MedlineGoogle Scholar
• 77 Lim JS, Lee K, Choi JN et al. Intracellular protein delivery by hollow mesoporous silica capsules with a large surface hole. Nanotechnology 23(8), 085101 (2012).
  MedlineGoogle Scholar
• 78 Lei C, Liu P, Chen B et al. Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J. Am. Chem. Soc. 132(20), 6906–6907 (2010).
  Medline CASGoogle Scholar
• 79 Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 462(7272), 449–460 (2009).
  Medline CASGoogle Scholar
• 80 Lee Y, Ishii T, Kim HJ et al. Efficient delivery of bioactive antibodies into the cytoplasm of living cells by charge-conversional polyion complex micelles. Angew. Chem. Int. Ed. Engl. 49(14), 2552–2555 (2010).
  Medline CASGoogle Scholar
• 81 Canton I, Massignani M, Patikarnmonthon N et al. Fully synthetic polymer vesicles for intracellular delivery of antibodies in live cells. FASEB J. 27(1), 98–108 (2013).
  Medline CASGoogle Scholar
• 82 Tyagi P, Barros M, Stansbury JW, Kompella UB. Light activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol. Pharm. 10(8), 2858–2867 (2013).
  Medline CASGoogle Scholar
• 83 Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6(Pt 1), 688–701 (2006).
  Medline CASGoogle Scholar
• 84 Berguig GY, Convertine AJ, Shi J et al. Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody–polymer conjugate. Mol. Pharm. 9(12), 3506–3514 (2012).
  Medline CASGoogle Scholar
• 85 Lackey CA, Press OW, Hoffman AS, Stayton PS. A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex. Bioconjug. Chem. 13(5), 996–1001 (2002).
  Medline CASGoogle Scholar
• 86 Li W, Guo Q, Zhao H et al. Novel dual-control poly(N-isopropylacrylamide-co-chlorophyllin) nanogels for improving drug release. Nanomedicine (Lond.) 7(3), 383–392 (2012).
  CASGoogle Scholar
• 87 Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 462(7272), 449–460 (2009).
  Medline CASGoogle Scholar
• 88 Global medical discovery. The finely regulating well-defined functional polymeric nanocarriers for anti-tumor immunotherapy. http://globalmedicaldiscovery.com/key-scientific-articles/the-finely-regulating-well-defined-functional-polymeric-nanocarriers-for-anti-tumor-immunotherapy.
  Google Scholar
• 89 Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58(7), 1408–1416 (1998).
  Medline CASGoogle Scholar
• 90 Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99(19), 1441–1454 (2007).
  Medline CASGoogle Scholar
• 91 Yahara T, Koga T, Yoshida S, Nakagawa S, Deguchi H, Shirouzu K. Relationship between microvessel density and thermographic hot areas in breast cancer. Surg. Today 33(4), 243–248 (2003).
  MedlineGoogle Scholar
• 92 Li W, Feng S, Guo Y. Tailoring polymeric micelles to optimize delivery to solid tumors. Nanomedicine (Lond.) 7(8), 1235–1252 (2012).
  Google Scholar
• 93 Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Deliv. Rev. 56(8), 1161–1176 (2004).
  Medline CASGoogle Scholar
• 94 Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319(5863), 627–630 (2008).
  Medline CASGoogle Scholar
• 95 Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release 146(3), 264–275 (2010).
  Medline CASGoogle Scholar
• 96 Wu K, Liu J, Johnson RN, Yang J, Kopecek J. Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew. Chem. Int. Ed. Engl. 49(8), 1451–1455 (2010).
  Medline CASGoogle Scholar
• 97 Li W, Feng SS, Guo Y. Block copolymer micelles for nanomedicine. Nanomedicine (Lond.) 7(2), 169–172 (2012).
  CASGoogle Scholar
• 98 Li W, Nakayama M, Akimoto J, Okano T. Effect of block compositions of amphiphilic block copolymers on the physicochemical properties of polymeric micelles. Polymer 52(17), 3783–3790 (2011).
  CASGoogle Scholar
• 99 Li W, Li J, Gao J et al. The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials 32(15), 3832–3844 (2011).
  Medline CASGoogle Scholar
• 100 Li W, Hong L, Ngai T, Huang H, He T, Wu C. A comparative study of chain dynamics of di-and tri-block copolymers in semidilute solution in a non-selective solvent. Chinese J. Polym. Sci. 22(6), 589–598 (2004).
  CASGoogle Scholar
• 101 Odian G. Principles of Polymerization (Chemistry) (4th Edition). Wiley-Blackwell Hobroke, NJ, USA (2004).
  Google Scholar
• 102 Sharp JM, Dickinson RB. Direct evaluation of DLVO theory for predicting long-range forces between a yeast cell and a surface. Langmuir 21(18), 8198–8203 (2005).
  Medline CASGoogle Scholar
• 103 Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930–4934 (2006).
  Medline CASGoogle Scholar
• 104 Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25(8), 1815–1821 (2008).
  Medline CASGoogle Scholar
• 105 Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9(2), E128–E147 (2007).
  Medline CASGoogle Scholar
• 106 Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22(19), 2406–2412 (2004).
  Medline CASGoogle Scholar
• 107 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751–760 (2007).
  Medline CASGoogle Scholar
• 108 Basarkar A, Singh J. Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice. Pharm. Res. 26(1), 72–81 (2009).
  Medline CASGoogle Scholar
• 109 Boudier A, Aubert-Pouessel A, Louis-Plence P et al. The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials 30(2), 233–241 (2009).
  Medline CASGoogle Scholar
• 110 Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum. Vaccin. 491(1), 5–12 (2008).
  Google Scholar
• 111 Liu Z, Winters M, Holodniy M, Dai H. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew. Chem. Int. Ed. Engl. 46(12), 2023–2027 (2007).
  Medline CASGoogle Scholar
• 112 Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16(1), 122–130 (2005).
  Medline CASGoogle Scholar
• 113 Nishiyama N, Bae Y, Miyata K, Fukushima S, Kataoka K. Smart polymeric micelles for gene and drug delivery. Drug Discov. Today Technol. 2(1), 21–26 (2005).
  Medline CASGoogle Scholar
• 114 Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J. Control. Release 132(3), 164–170 (2008).
  Medline CASGoogle Scholar
• 115 Lee ES, Na K, Bae YH. Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 5(2), 325–329 (2005).
  Medline CASGoogle Scholar
• 116 Takae S, Miyata K, Oba M et al. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J. Am. Chem. Soc. 130(18), 6001–6009 (2008).
  Medline CASGoogle Scholar
• 117 Zhu J, Tang A, Law LP et al. Amphiphilic core-shell nanoparticles with poly(ethylenimine) shells as potential gene delivery carriers. Bioconjug. Chem. 16(1), 139–146 (2005).
  Medline CASGoogle Scholar
• 118 Zhang Z, Tongchusak S, Mizukami Y et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 32(14), 3666–3678 (2011).
  Medline CASGoogle Scholar
• 119 Krishnamachari Y, Salem AK. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv. Drug Deliv. Rev. 61(3), 205–217 (2009).
  Medline CASGoogle Scholar
• 120 Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771–782 (2008).
  Medline CASGoogle Scholar
• 121 Nochi T, Yuki Y, Takahashi H et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater. 9(7), 572–578 (2010).
  Medline CASGoogle Scholar
• 122 Poland CA, Duffin R, Kinloch I et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol. 3(7), 423–428 (2008).
  Medline CASGoogle Scholar
• 123 Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2(8), 469–478 (2007).
  Medline CASGoogle Scholar
• 124 Moghimi SM. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta 1590(1–3), 131–139 (2002).
  Medline CASGoogle Scholar
• 125 Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61(3), 1095–1099 (2001).
  Medline CASGoogle Scholar
• 126 Tarhini AA, Cherian J, Moschos SJ et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J. Clin. Oncol. 30(3), 322–328 (2012).
  Medline CASGoogle Scholar
• 127 Webster WS, Thompson RH, Harris KJ et al. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. 179(5), 2860–2869 (2007).
  Medline CASGoogle Scholar
• 128 Vyas SP, Gupta PN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines 6(3), 401–418 (2007).
  Medline CASGoogle Scholar